+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

R

Actively Recruiting

Non-small cell lung cancer NSCLC is a common type of lung cancer where abnormal cells grow quickly, affecting lung function. This study focuses on advanced stages of squamous and nonsquamous NSCLC that cannot be surgically removed or have spread to other body parts. Researchers are investigating TAK-928, a new drug designed to activate immune cells called T cells to better attack and destroy tumor cells, comparing it to the standard treatment, docetaxel, in adults with this condition. TAK-928 is a bispecific monoclonal antibody administered through intravenous infusion that targets specific immune pathways to stimulate T cells and natural killer cells against cancer. Participants will receive either TAK-928 or docetaxel, also given by IV infusion. Treatment may continue for up to 24 months, with duration depending on individual response and side effects. The trial includes a randomized, parallel design to evaluate the efficacy and safety of TAK-928 compared to docetaxel. Participants will visit the study clinic multiple times for assessments including imaging scans to measure tumor response, laboratory tests, and questionnaires about quality of life and symptoms. Researchers will monitor treatment effects, side effects, and survival outcomes for up to 26 months. Safety and immune response will also be tracked throughout the study, with ongoing evaluations until treatment ends. Participant involvement may last up to two years or more depending on individual circumstances.

Age: 18Years +All GendersPhase 3
50 locations
P

Actively Recruiting

Researchers are conducting a phase 1, multicenter, nonrandomized, open-label study to evaluate YL201 in patients with advanced solid tumors that have not responded to current treatments or lack standard therapy options. The study includes two parts Part 1 focuses on finding the maximum tolerated dose and recommended dose levels through dose escalation, while Part 2 enrolls patients with selected tumor types to further assess safety and efficacy of YL201. Participants will receive YL201 as an intravenous infusion once every three weeks in cycles. Some patients may receive YL201 alone at different dosages or in combination with atezolizumab during each 21-day cycle. Part 1 involves dose escalation cohorts to determine appropriate dosing, followed by Part 2 dose expansion cohorts to better define safety and evaluate treatment responses. Throughout the study, participants undergo tumor evaluations using RECIST criteria, laboratory tests, and safety monitoring to track adverse events, dose-limiting toxicities, and pharmacokinetics. For prostate cancer patients, prostate-specific antigen response and progression-free survival will be measured. The study lasts approximately 36 months, with ongoing assessments of tumor response, survival, and laboratory abnormalities conducted at regular intervals.

Age: 18Years +All GendersPhase 1Phase 2
45 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.

Age: 65Years +All GendersPhase 3
163 locations
P

Actively Recruiting

Researchers are evaluating a new mRNA vaccine that combines protection against both seasonal flu and COVID-19 in healthy adults aged 65 to 85 years. This early-stage Phase 1 study aims to assess the safety and immune response of this investigational vaccine compared to standard licensed flu and COVID-19 vaccines. The study is focused on measuring side effects and how well the vaccine builds protection against both infections. Participants will receive a single intramuscular injection of either one of three dose levels of the investigational mRNA combination vaccine, a licensed seasonal flu vaccine, or a licensed COVID-19 vaccine. The study groups are randomized and observer-blind. The investigational vaccine is given as a single dose, with three different dosage levels being tested sequentially for safety and immune response. During the study, participants will be monitored for side effects from the day of vaccination through several time points up to 181 days. Blood samples will be collected at specified intervals to evaluate immune responses against flu and COVID-19. The main measures include the number of participants experiencing laboratory abnormalities and adverse events, as well as immune protection markers such as antibody levels and seroconversion rates. The total participation spans from vaccination day through about six months of follow-up.

Age: 65Years - 85YearsAll GendersPhase 1
12 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a single dose of Sanofis Omicron subvariant-based Nuvaxovid vaccine in people aged 65 and older, as well as in individuals aged 12 to 64 who have at least one underlying health condition that increases their risk of severe COVID-19. Participants must have previously received a COVID-19 vaccine at least 90 days before getting this study vaccine. Participants will receive one intramuscular injection of the Nuvaxovid vaccine on the first day of the study. The study duration for each participant is about three months, including follow-up visits and telephone calls to monitor their health and immune response after vaccination. Throughout the study, participants will have visits on Day 1, Day 9 telephone call, Day 29, and Day 91 telephone call to assess safety and immune response. Researchers will measure antibody levels against the Omicron variant before vaccination and 28 days after. They will also monitor for any immediate or delayed side effects, including local reactions, systemic symptoms, and any serious adverse events during the three-month follow-up.

Age: 12Years +All GendersPhase 4
20 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a new pneumococcal vaccine called PG4 compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC in children and adolescents. The study aims to see how well the new vaccine helps the body fight germs that cause pneumonia, meningitis, and ear infections. It includes children aged 15 months to less than 18 years, some of whom may have previously received pneumococcal vaccines. Participants will be divided into three age groups 15 months to under 2 years, 2 to under 5 years, and 5 to under 18 years. Within each group, participants will be randomly assigned in a 21 ratio to receive a single injection of either the new vaccine PG4 or the existing 20vPnC vaccine, given in the arm or thigh. The study is conducted across multiple countries including the United States and Puerto Rico. Each participant will be involved for about 6 months, attending two clinic visitsone for vaccination and one for follow-upand one telephone follow-up. Blood samples will be collected at visits to measure immune response, and participants will be monitored for local and systemic reactions, adverse events, and serious adverse events throughout the study period. The study evaluates immune system protein levels and antibody activity one month after vaccination to compare the vaccines effects.

Age: 15Months - 17YearsAll GendersPhase 3
77 locations